Associations between Serum Interleukins (IL‐1<i>β</i>, IL‐2, IL‐4, IL‐6, IL‐8, and IL‐10) and Disease Severity of COVID‐19: A Systematic Review and Meta‐Analysis
Yuanmin Chang, Mengru Bai, Qinghai You
Abstract
Background . To investigate the association between interleukins (IL‐1 β , IL‐2, IL‐4, IL‐6, IL‐8, and IL‐10) and the disease severity of coronavirus disease 2019 (COVID‐19). Materials and Methods . We systematically searched records investigating the role of interleukins (IL‐1 β , IL‐2, IL‐4, IL‐6, IL‐8, and IL‐10) in COVID‐19 patients in Web of Science, Pubmed, and Embase through December 2020. Data were extracted and pooled, and the weighted mean difference (WMD) and its 95% confidence interval (CI) were calculated. The funnel plot and the nonparametric trim and fill method were used to visualize and adjust the publication bias. Results . In total, 61 studies enrolled 14,136 subjects (14,041 patients and 95 healthy subjects) were enrolled in this meta‐analysis. Our results showed that serum IL‐2, IL‐4, IL‐6, and IL‐10 levels were elevated in COVID‐19 patients compared to healthy controls, and IL‐6, IL‐8, and IL‐10 levels were increased in severe COVID‐19 cases compared to nonsevere patients. Additionally, the levels of IL‐1 β , IL‐6, and IL‐8 were elevated in nonsurvivor patients compared to survivors. For patients in the intensive care unit (ICU), IL‐6 and IL‐8 levels were increased than that in non‐ICU patients. Conclusions . Elevated levels of IL‐6, IL‐8, and IL‐10 were associated with the disease severity of COVID‐19, and elevated levels of IL‐1 β , IL‐6, and IL‐8 were related to the prognosis of COVID‐19 patients, which could be used to evaluate COVID‐19 patients’ disease severity and prognosis.